Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

COSMOS-Mind: Daily Multivitamin Improves Cognition in Older Adults

Three years of a daily multivitamin-mineral supplement improved memory, and cognitive and executive function in older adults, according to data from the COSMOS-Mind study. Three years of administering cocoa extract every day had no effect on cognitive function, however. “This is the first positive, large-scale, long-term study to show that…

Symposium Highlights Research, Care Disparities Among Latinos

Improved access to high-quality healthcare and research for Latinos living with Alzheimer’s disease and related dementia are needed, according to a summary report from the second Latinos & Alzheimer’s Symposium. Understanding underlying disease-related processes unique to Latino populations, and identifying social and environmental risk factors for this group also…

Lower Levels of Tau Marker Seen With Aduhelm in Phase 3 Trials

Treatment with Aduhelm (aducanumab) showed a significant correlation with lower blood levels of p-tau181, a disease biomarker, and lesser cognitive and functional decline in Alzheimer’s patients, according to a recent data analysis of two Phase 3 clinical trials. The data, analyzed from around 7,000 blood samples collected from more than…

Mouse Study: 4 Approved Meds Are Potential Alzheimer’s Treatments

Detailed molecular signatures in three mouse models of Alzheimer’s disease at different disease stages allowed for identification of four approved medicines that may be potential Alzheimer’s treatments, a study revealed. The four medications that demonstrated efficiency are now used to treat hypertension (high blood pressure) and inflammation in humans.

Gantenerumab Lowers Key Protein Levels in Early-onset Disease Trial

The investigational therapy gantenerumab significantly lowered levels of established biomarkers in a rare, inherited form of early-onset Alzheimer’s disease, despite failing to slow cognitive decline or memory loss in symptomatic and asymptomatic patients, according to data from a Phase 2/3 clinical trial. Based on these results, enrolled patients…